Abstracts tagged "Anticoagulation"

Abstract Number: 164 • 2018 ACR/ARHP Annual Meeting
Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study
Massimo Radin¹, Irene Cecchi², Elena Rubini³, Anna Scotta⁴, Roberta Rolla⁵, Barbara Montaruli⁶, Patrizia Pergolini⁵, Giulio Mengozzi⁴, Elena Muccini⁴, Antonella Vaccarino⁷, Dario Roccatello⁸ and Savino Sciascia⁹, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴University of Turin, Turin, Italy, ⁵University of Turin, Novara, Italy, ⁶Ospedale Mauriziano, Turin, Italy, ⁷Ospedale S. Giovanni Bosco, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Correct interpretation of lupus anticoagulant (LA) tests is crucial for diagnosis of antiphospholipid syndrome (APS). However, testing patients during vitamin K antagonist (VKA) or…
Abstract Number: 854 • 2018 ACR/ARHP Annual Meeting
First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Ozan Unlu², Danieli Andrade³, Alessandra Banzato⁴, Maria Tektonidou⁵, Amaia Ugarte⁶, Maria Gerosa⁷, Hannah Cohen⁸, David Branch⁹, Guilherme Ramires de Jesus¹⁰, Angela Tincani¹¹, Paul R. Fortin¹², Michelle Petri¹³, Ignasi Rodriguez¹⁴, Jason S Knight¹⁵, Tatsuya Atsumi¹⁶, Rohan Willis¹⁷, Robert Roubey¹⁸ and Doruk Erkan¹⁹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA., New York, NY, ³Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁵Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁶Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁷Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁸Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁹Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁰Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹University and Spedali Civili of Brescia, Brescia, Italy, ¹²Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷301 University Blvd, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA, Galveston, TX, ¹⁸Rheumatology, Allergy, and Immunology, Department of Medicine and Thurston Arthritis Research Center, Division of Rheumatology, Allergy and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, John Conklin², Robert Apilado², Tyler O'Malley², JoAnne Ligayon², Leilani Wolover² and Thierry Dervieux², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…
Abstract Number: 2782 • 2018 ACR/ARHP Annual Meeting
Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
Mahjabeen Haq¹, Danielle Schwartz¹, Monica Weinberg¹, Jillian Cepeda¹, Erin Taub², Asha Patniak³ and Qingping Yao⁴, ¹Department of Medicine-Rheumatology, Allergy, and Immunology Division, Stony Brook University Hospital, stony brook, NY, ²Department of Medicine, Stony Brook University Hospital, stony brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Rheumatology, Allergy and Immunology, Stony Brook University Hospital, Stony Brook, NY
Background/Purpose: Giant cell arteritis (GCA) and Temporal arteritis (TA) is characterized by chronic granulomatous inflammation in medium and large-sized vessels. It affects 20 in 100,000…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 1064 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients
Ozan Unlu¹, Hannah Cohen², Maria Jose Cuadrado³, Paul R. Fortin⁴, Guilherme Ramires de Jesus⁵, Maria Gerosa⁶, Jason K Knight⁷, Vittorio Pengo⁸, Michelle Petri⁹, Esther Rodriguez-Almaraz¹⁰, Stephane Zuily^11,12, Doruk Erkan¹³ and On Behalf of APS ACTION .¹⁴, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²University College London, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁴Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁵Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁷University of Michigan, Ann Arbor, MI, ⁸Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain, ¹¹CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France, ¹²Inserm, UMR_S 1116, Nancy, France, ¹³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁴., New York, NY
Background/Purpose: Direct oral anticoagulants (DOACs) are approved for the treatment of venous, and prevention of venous/arterial thrombosis. There have been case reports/ series where DOACs…
Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Maria Ester Simeira Fonseca¹, Michelle Lopes², Christiane Pereira Gouvea³ and Danieli Andrade⁴, ¹Rheumatology, University of São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ³Hematology, University of São Paulo, São Paulo, Brazil, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…
Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Alina Casian¹, Shirish Sangle (joint 1st author)², Sotiria Manoustathopoulou³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Medicine, St. Thomas' Hospital, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…
Abstract Number: 11 • 2014 ACR/ARHP Annual Meeting
Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome
Alonso Turrent¹, Gabriela Hernandez-Molina² and Antonio R. Cabral³, ¹Immunology and Rheumatology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose: The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been…
Abstract Number: L7 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome without Anticoagulation: 0utcome of 50 Patients
Cécile Yelnik^1,2, Geoffrey Urbanski^1,3, Hélène Maillard^2,4, Aurélia Lanteri^1,2, Noémie Chanson^1,5, Chloé Stavris^1,3, Sandrine Morell-Dubois^1,3, David Launay^3,6,7, Sylvain Dubucquoi^6,7,8, Eric Hachulla^1,3,6, Pierre-Yves Hatron^1,3 and Marc Lambert^1,2, ¹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ²Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³Service de médecine interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, Lille, France, ⁴Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France, ⁵Hôpital Claude Huriez, Lille, France, ⁶EA 2686, Lille, Lille, France, ⁷Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ⁸Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France
Background/Purpose: Long-term anticoagulation is currently the standard treatment for arterial or venous antiphospholipid syndrome (APS). However, in daily clinical practice, the question of withdrawing anticoagulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].